Literature DB >> 30484240

Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.

Alvise Berti1,2, Roberto Caporali3, Carlomaurizio Montecucco3, Giuseppe Paolazzi4, Sara Monti3,5.   

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) usually affect adults and older populations. The well recognized clinical (i.e., granulomatosis with polyangiitis [GPA], microscopic polyangiitis, and eosinophilic GPA) and serological phenotypes (i.e., anti-MPO-ANCA, anti-PR3-ANCA and ANCA negative) within AAV differ substantially for clinical, demographic, and epidemiological features, including age at presentation. Whether and how aging could contribute to the clinical expression of these disease phenotypes is intriguing and still overlooked. In addition, despite being predominantly a disease of the elderly, most of the studies analyzing drug interventions and the clinical trials on AAV explicitly excluded older patients, limiting the understanding of the disease in this subset of patients. In elderly patients induced with cyclophosphamide, a lower dose of treatment for patients aged 60 years or older and with reduced renal function has been recommended. Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are two primary systemic vasculitides involving large vessels that differ in age at presentation, with GCA patients being at least 10 years older than TAK patients. Different treatment approaches are effective in these conditions. However, a few authors have suggested that they might be considered expressions of the same clinical syndrome, rather than two different diseases. Novel insights into the role of senescence-related immunological and vascular processes might help to interpret the link between these two conditions. Overall, the impact of aging on all these vasculitides is complex and not easy to analyze. So far, few studies focusing on this topic have been published. We reviewed data on the clinical presentation, epidemiology, therapy, and disease- and treatment-related complications in patients affected by these vasculitides, highlighting the differences in young versus elderly subjects.

Entities:  

Mesh:

Year:  2019        PMID: 30484240     DOI: 10.1007/s40266-018-0617-4

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  106 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.

Authors:  Jan H Schirmer; Marvin N Wright; Reinhard Vonthein; Kristine Herrmann; Bernhard Nölle; Marcus Both; Frank O Henes; Andreas Arlt; Wolfgang L Gross; Susanne Schinke; Eva Reinhold-Keller; Frank Moosig; Julia U Holle
Journal:  Rheumatology (Oxford)       Date:  2015-08-20       Impact factor: 7.580

3.  ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.

Authors:  L Harper; C O Savage
Journal:  Rheumatology (Oxford)       Date:  2004-12-21       Impact factor: 7.580

4.  Prognosis of large-vessel giant cell arteritis.

Authors:  W A Schmidt; A Moll; A Seifert; B Schicke; E Gromnica-Ihle; A Krause
Journal:  Rheumatology (Oxford)       Date:  2008-07-14       Impact factor: 7.580

Review 5.  Epidemiology of large-vessel vasculidities.

Authors:  Bethan L Richards; Lyn March; Sherine E Gabriel
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-12       Impact factor: 4.098

Review 6.  The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist.

Authors:  Sara Monti; Alberto Floris; Cristina Ponte; Wolfgang A Schmidt; Andreas P Diamantopoulos; Claudio Pereira; Jennifer Piper; Raashid Luqmani
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

7.  Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies.

Authors:  Ju Ann Tan; Natasha Dehghan; Wenjia Chen; Hui Xie; John M Esdaile; J Antonio Avina-Zubieta
Journal:  Ann Rheum Dis       Date:  2017-05-03       Impact factor: 19.103

8.  Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment.

Authors:  Luca Santoro; Ferruccio D'Onofrio; Simone Bernardi; Elisa Gremese; Gianfranco Ferraccioli; Angelo Santoliquido
Journal:  Rheumatology (Oxford)       Date:  2013-01-07       Impact factor: 7.580

9.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

10.  All-Cause and Cause-Specific Mortality in Patients With Granulomatosis With Polyangiitis: A Population-Based Study.

Authors:  Ju Ann Tan; Hyon K Choi; Hui Xie; Eric C Sayre; John M Esdaile; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-01       Impact factor: 4.794

View more
  1 in total

1.  Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study.

Authors:  Luca Quartuccio; Miriam Isola; Dario Bruno; Elena Treppo; Laura Gigante; Francesca Angelotti; Riccardo Capecchi; Gianfranco Vitiello; Elena Cavallaro; Antonio Tavoni; Silvia Laura Bosello; Daniele Cammelli; Salvatore De Vita; Elisa Gremese
Journal:  J Transl Autoimmun       Date:  2020-11-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.